Patents Examined by Timothy A. Worrall
-
Patent number: 6080847Abstract: The invention provides three human proteins associated with cell proliferation, referred to collectively as "APOP" and individually as "APOP-1", "APOP-2", and "APOP-3", and polynucleotides which identify and encode APOP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of APOP.Type: GrantFiled: December 4, 1997Date of Patent: June 27, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Henry Yue, Preeti Lal, Purvi Shah, Neil C. Corley
-
Patent number: 6080848Abstract: The invention provides a human human brain-associated protein (HBAP-1) and polynucleotides which identify and encode HBAP-1. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HBAP-1.Type: GrantFiled: May 1, 1998Date of Patent: June 27, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Sven Henrichwark, Janice Au-Young, Karl J. Guegler, Neil C. Corley, Mariah R. Baughn
-
Patent number: 6066718Abstract: The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy.Type: GrantFiled: September 27, 1993Date of Patent: May 23, 2000Assignees: Novartis Corporation, Tanox Biosystems, Inc.Inventors: Norman Hardman, Frank Kolbinger, Jose Saldanha
-
Patent number: 6048970Abstract: The invention provides two human prostate growth-associated membrane proteins (PGAMP) and polynucleotides which identify and encode PGAMP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of PGAMP.Type: GrantFiled: May 22, 1998Date of Patent: April 11, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
-
Patent number: 6008337Abstract: The invention provides human cell cycle related proteins (CCRP) and polynucleotides which identify and encode CCRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of CCRP.Type: GrantFiled: February 27, 1998Date of Patent: December 28, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Henry Yue, Preeti Lal
-
Patent number: 5998583Abstract: A novel death agonist, BID, which contains only a BH3 domain but not the BH1, BH2, BH4 or membrane anchoring domains found in related BCL-2 family members is provided along with derivatives of BID, bid polynucleotides and derivatives thereof and compositions and uses therefor.Type: GrantFiled: September 5, 1997Date of Patent: December 7, 1999Assignee: Washington UniversityInventor: Stanley J. Korsmeyer
-
Patent number: 5990346Abstract: A prostaglandin having formula (I), (II), or (III): ##STR1## a process of production thereof, and inhibitors of cell migration caused by chemokines containing (I) or (II) as an active ingredient.Type: GrantFiled: February 26, 1997Date of Patent: November 23, 1999Assignee: Teijin LimitedInventors: Kenichiro Kataoka, Toru Minoshima, Tatsuki Shiota, Takaharu Tsutsumi, Takahiko Hada, Hiroko Tanaka, Takuya Morita, Noriaki Endo
-
Patent number: 5980912Abstract: Methods and compositions for potentiating an immune response are disclosed which incorporate chitosan as an immunopotentiating adjuvant. Administration of the compositions of the invention is effected by various routes.Type: GrantFiled: March 25, 1997Date of Patent: November 9, 1999Assignee: Zonagen, Inc.Inventors: Joseph S. Podolski, Mitzi L. Martinez
-
Patent number: 5981201Abstract: Novel methods of detecting and treating breast cancer are described.Type: GrantFiled: June 16, 1997Date of Patent: November 9, 1999Assignee: Beth Israel Deaconess Medical CenterInventors: Hava Avraham, Jerome E. Groopman
-
Patent number: 5977319Abstract: The invention relates to specific binding members for estradiol and materials and methods relating thereto, in particular antibodies or binding domains thereof which have high affinities (low dissociation constants) for estradiol and low cross-reactivity for other steroids. The invention further provides means to make such binding members, assay methods for the detection and/or quantitation of estradiol, and nucleic acid encoding said binding members, which nucleic acid may be used for their production. Preferred binding members include those with CDR regions of the D12 antibody heavy and light chain domains (SEQ ID NO:2 and SEQ ID NO:12 respectively).Type: GrantFiled: October 21, 1997Date of Patent: November 2, 1999Assignee: Cambridge Antibody Technology LimitedInventors: Anthony Richard Pope, Kevin Pritchard, Andrew James Williams, Kevin Stuart Johnson
-
Patent number: 5977311Abstract: The present invention relates to complexes of the 53BP2 protein with proteins identified as interacting with 53BP2 by a yeast two hybrid assay system. The proteins identified to interact with 53BP2 are .beta.-tubulin, p62, hnRNP G, and three gene products, 53BP2-IP1, 53BP2-IP2, and 53BP2-IP3 encoded, in part, by the EST R72810 sequence. Thus, the invention provides complexes of 53BP2 and .beta.-tubulin, p62, hnRNP G, 53BP2-IP1, 53BP2-IP2, and 53BP2-IP3 and derivatives, fragments and analogs thereof. The invention also provides the 53BP2-IP1, 53BP2-IP2 and 53BP2-IP3 genes and proteins and derivatives, fragments and analogs thereof. Methods of screening the complexes for efficacy in treating and/or preventing certain diseases and disorders, particularly cancer, autoimmune disease and neurodegenerative disease are also provided.Type: GrantFiled: September 23, 1997Date of Patent: November 2, 1999Assignee: CuraGen CorporationInventors: Krishnan Nandabalan, Meijia Yang, Vincent Peter Schulz
-
Patent number: 5972626Abstract: Disclosed is a method for detecting neoplastic cells in a tissue sample by examining the cells for centrosomal abnormalities such as ectopic localization of centrosomal proteins, hypertrophic centrosomes, and supernumerary centrosomes.Type: GrantFiled: July 30, 1997Date of Patent: October 26, 1999Assignee: University of MassachusettsInventor: Stephen J. Doxsey
-
Patent number: 5965144Abstract: Methods and compositions for potentiating an immune response are disclosed which incorporate chitosan as an immunopotentiating adjuvant. Administration of the compositions of the invention is effected by various routes.Type: GrantFiled: April 24, 1998Date of Patent: October 12, 1999Assignee: Zonagen, Inc.Inventors: Joseph S. Podolski, Mitzi L. Martinez
-
Patent number: 5965131Abstract: An improvement in in vivo pretargeting methods for delivering diagnostic or therapeutic agents to a target site in a mammal uses a clearing agent that binds to the target-binding site of the targeting species, whereby non-bound primary targeting species is cleared from circulation but the clearing agent does not remove the bound primary targeting species. Anti-idiotype antibodies and antibody fragments are preferred clearing agents. Fast clearance is achieved by glycosylating the clearing agent with sugar residues that bind to the hepatic asialoglycoprotein receptor.Type: GrantFiled: October 9, 1996Date of Patent: October 12, 1999Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, Serengulam V. Govindan, Habibe Karacay
-
Patent number: 5955593Abstract: A novel death agonist, BID, which is related to the BCL-2 family of apoptosis regulating proteins only in the conserved BH3 domain, is provided along with encoding polynucleotides. BID polypeptides and derivatives thereof are useful in modulating apoptosis. Polynucleotides encoding BID polypeptides and derivatives thereof are useful as templates for recombinantly expressing BID polypeptides, as probes for detecting endogenously expressed BID polynucleotides, and in gene therapy for treating or preventing disease. Methods for modulating inappropriate expression of BID using BID antisense molecules or anti-BID antibodies are also provided. In addition, screening assays for identifying agents which modulate binding between BID and other BCL-2 family members are provided.Type: GrantFiled: September 9, 1996Date of Patent: September 21, 1999Assignee: Washington UniversityInventor: Stanley J. Korsmeyer
-
Patent number: 5952464Abstract: The invention relates to a labelled peptide compound, wherein the peptide has a selective neurotensin receptor affinity and is represented by the general formulaR.sub.1 -(.sup.1 Pro).sub.n -.sup.2 Xaa-.sup.3 Xbb-.sup.4 Xcc-.sup.5 Xdd-.sup.6 Xee-.sup.7 Leu-OH (SEQ ID NO:2) (I)wherein:R.sub.1 is a (C.sub.1 -C.sub.3)alkanoyl group, an arylcarbonyl group, an aryl-(C.sub.1 -C.sub.3)alkanoyl group, or a chelating group attached by an amide bond or through a spacing group to the peptide molecule;Xaa and Xbb are each individually Arg or Lys;Xcc is an unsubstituted or substituted cyclic amino acid, preferably selected from Pro and Hyp;Xdd is Tyr, Trp or Phe;Xee is Leu, Ile or t.-butylalanine; andn is 0 or 1;and wherein said peptide is labelled with (a) a metal isotope, or (b) with a radioactive halogen isotope; on the understanding that:(i) if the label is a metal isotope, R.sub.Type: GrantFiled: July 21, 1997Date of Patent: September 14, 1999Assignee: Mallinckrodt Inc.Inventors: John Mertens, Dirk Tourwe, Marc Ceusters
-
Patent number: 5928964Abstract: A system and method is provided for anisotropically etching a silicon nitride layer (12) in an ion-assisted plasma reactor. A chuck (34) supports a photoresist layer (10), the silicon nitride layer (12), and a semiconductor water (14). A chuck temperature controller (36) is provided for adjusting the temperature of the chuck (34) to either increase or decrease the etch bias of the silicon nitride layer (12) to achieve an optimal etch bias.Type: GrantFiled: December 18, 1996Date of Patent: July 27, 1999Assignee: Texas Instruments IncorporatedInventor: Keith J. Brankner
-
Patent number: 5910573Abstract: The present invention describes a new class of antigen binding molecules which contain Fv-fragments of an antibody but do not use the constant antibody domains. They can also dimerize with other antibody fragment molecules or with non-antibody fragment molecules to form bi- or multifunctional antibody-fragment fusion proteins and so-called miniantibodies, respectively. The new fusion proteins can be used in the broad field of diagnostic and therapeutical medicine.Type: GrantFiled: July 22, 1994Date of Patent: June 8, 1999Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Andreas Pluckthun, Peter Pack